LumiraDx Investor Presentation Deck
Southern Sweden Region: Performance
Enables Novel Testing Opportunities and Use Cases
Previous challenges with
D-Dimer testing
Thromboembolic conditions are a
leading cause of death, may be
ruled out with D-Dimer test
Rapid D-Dimer testing program in
Kalmar region discontinued
High level of false positive results
Patient stress and unnecessary
hospital admissions
lumiraDx™
LumiraDx program
LumiraDx Platform evaluated and
selected for POC testing
Lab comparable performance
Fingerstick blood sample
Portable, fast, reliable, and
easy to use at point of care
Testing implemented at 24 sites,
GP offices
Portability Mobile team
opportunity
=
Copyright © 2022 LumiraDx Ltd. All Rights Reserved. Worldwide
Future plans and
opportunities
Fingerstick sampling enables
expansion of POC and new use
cases for D-Dimer
Portability for mobile teams,
emergency dept, and ambulance
Range of analytes, Troponin,
CRP, increase customer value
Correct and rapid test results lead
to better outcomes and overall
lower costs
Case Study
Connectivity efficiency in admin
of results, operators, etc.
48View entire presentation